Nisin Z
Also known as: E234, Lantibiotic Nisin Z, Nisin variant Z, Nisin Z, Nisin Z variant, Nisin Z-3, NisZ
Source Nisin Z at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nisin Z is a naturally occurring lantibiotic peptide produced by Lactococcus lactis. It belongs to the antimicrobial peptide family and is used primarily in research settings. The molecule exhibits potent activity against Gram‑positive bacteria and has been investigated for veterinary applications such as treating bovine mastitis, as well as for potential oral health and anticancer uses in laboratory studies.
Mechanism of Action
Nisin Z is a ribosomally synthesized peptide that undergoes post‑translational modifications forming lanthionine bridges. Its antimicrobial effect stems from binding to lipid II in bacterial membranes, triggering rapid depolarisation and pore formation that releases low‑molecular‑weight contents. Some studies also suggest an additional inhibition of peptidoglycan (murein) synthesis, contributing to its bactericidal activity against susceptible Gram‑positive organisms.
What the Research Shows
The literature on Nisin Z spans genetics, engineering, and applied studies. Early work described the nisZ gene and the suite of biosynthetic, transport, and immunity genes required for production. Protein‑engineering efforts have generated mutant lantibiotics to map regions critical for activity. In a controlled trial with lactating cows, intramammary infusion of Nisin Z (2.5 × 10⁶ IU daily for three days) combined with a Staphylococcus aureus bacterin markedly reduced intramammary S. aureus infection, somatic‑cell counts, and improved milk protein and fat. Review articles note its in‑vitro synergy with ampicillin against Pseudomonas fluorescens and activity against MRSA, as well as emerging evidence of antitumor effects in oral cancer models. Nanotechnology‑based delivery systems are being explored, though still at an early stage.
Reported Benefits
Animal studies demonstrate that Nisin Z can lower bacterial load and inflammation in subclinical mastitis, leading to better milk quality. In vitro data show enhanced activity when combined with conventional antibiotics, suggesting a potential role in combating resistant strains such as MRSA. Preliminary reviews also highlight dual antimicrobial and antitumor properties, positioning Nisin Z as a candidate for oral infection control and cancer adjunct therapy, pending further validation.
Limitations of the Evidence
Evidence for therapeutic use is limited to a single bovine trial and numerous in‑vitro or animal‑model studies; no human clinical trials have been reported. The peptide’s stability, optimal dosing, and delivery methods remain unresolved, and the synergy observations have not been confirmed in vivo. Regulatory approval for medical indications is absent, and the current status is restricted to research applications.
Safety Considerations
No adverse events were reported in the bovine mastitis trial, and Nisin Z is widely regarded as safe as a food preservative. However, safety data for systemic or topical therapeutic use in humans are lacking. Reviews emphasize the need for comprehensive in‑vivo toxicity and pharmacokinetic studies before clinical deployment, especially given the potential for immune reactions to peptide therapeutics.
How It Is Administered
Research applications of Nisin Z have employed intramammary infusion in cows, as well as oral and topical formulations in experimental settings. The peptide is typically delivered in aqueous solutions, and emerging nanocarrier systems aim to improve stability and tissue penetration. All routes are experimental and used under controlled laboratory conditions.
Routes of Administration
Goals & Uses
- Topical wound infection managementAntimicrobial/Wound CareLow
- Antimicrobial activity against MRSAAntibacterialModerate
- Food preservation / biopreservationFood SafetyHigh
- Inhibition of Clostridium and Bacillus spore outgrowthAntibacterialModerate
- Food preservationAntimicrobialHigh
- Treatment of bovine mastitisVeterinary AntimicrobialModerate
Contraindications
- Severe peptide allergyAllergyHigh
- Disruption of normal Gram-positive microbiomeMicrobiome ConcernModerate
- Known hypersensitivity to nisin or lantibioticsAllergy/HypersensitivityHigh
Adverse Effects
- Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
- Local irritationDermatologicUncommon
- Gastrointestinal discomfortGastrointestinalUncommon
- Disruption of commensal Gram-positive floraMicrobiomeUnknown
Drug Interactions
- Proteolytic enzymes (digestive)Moderate
- Other antibiotics (synergy)Low
Population Constraints
- Neonates and infantsPediatricRelative
- Infants < 1 monthAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: food additive (E234)Authorized under EU food additive regulations.
- United StatesApprovedApproved: food preservativeGRAS (Generally Recognized As Safe) for use in a variety of food products.
- United KingdomApprovedApproved: food additiveRecognized under UK food additive legislation.
GRAS status in the United States; approved as food additive E234 in the European Union; considered safe for general consumption but not evaluated as a therapeutic drug.
Evidence & Sources
- Journal ArticleModerateGuan R, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateKuipers OP, et al.1996-01-01T00:00:00.000000Z
- Journal ArticleModerateEntian KD, de Vos WM1996-01-01T00:00:00.000000Z
- Journal ArticleModerateRodríguez JM, Dodd HM1996-01-01T00:00:00.000000Z
- Journal ArticleModerateBiswaro LS, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleModerateCarvalho de Paula AE, Silva Siqueira C, Lorenzón EN2025-01-01T00:00:00.000000Z
Frequently Asked Questions
Can Nisin Z be used to treat human infections?
Currently Nisin Z is not approved for human therapeutic use. Existing data are limited to animal studies and in‑vitro experiments, so clinical efficacy and safety in humans remain unproven.
How does Nisin Z differ from the more common Nisin A?
Nisin Z differs from Nisin A by a single amino‑acid substitution at position 27 (asparagine replaces histidine). This small change can affect solubility and activity, and it is the basis for separate research on the Z variant.
Is Nisin Z safe as a food preservative?
Yes, Nisin (including the Z variant) has a long history of use as a food preservative and is considered safe for consumption at approved levels. Therapeutic dosing, however, has not been evaluated for safety.
What are the main challenges in developing Nisin Z as a drug?
Key challenges include ensuring peptide stability in the body, achieving effective concentrations at target sites, avoiding rapid degradation, and generating robust safety data. Formulation strategies such as nanocarriers are being investigated to address these issues.
What is Nisin Z?
Nisin Z is a naturally occurring lantibiotic peptide produced by Lactococcus lactis. It belongs to the antimicrobial peptide family and is used primarily in research settings. The molecule exhibits potent activity against Gram‑positive bacteria and has been investigated for veterinary applications such as treating bovine mastitis, as well as for potential oral health and anticancer uses in laboratory studies.
What is Nisin Z used for?
Nisin Z is educationally associated with: Topical wound infection management, Antimicrobial activity against MRSA, Food preservation / biopreservation, Inhibition of Clostridium and Bacillus spore outgrowth, Food preservation, Treatment of bovine mastitis. Educational only — not medical advice.
How is Nisin Z administered?
Recorded routes of administration: Oral, Topical.
What are the potential side effects of Nisin Z?
Reported adverse effects include: Allergic reaction, Local irritation, Gastrointestinal discomfort, Disruption of commensal Gram-positive flora. This list is not exhaustive — consult a qualified clinician.
Who should avoid Nisin Z?
Recorded contraindications: Severe peptide allergy, Disruption of normal Gram-positive microbiome, Known hypersensitivity to nisin or lantibiotics. Consult a qualified clinician before use.